Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.33 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.33 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.33 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19157912 | 0.82 | PHF8 (0.42) | PHF8KDM4CKDM2BKDM2APDE2A | |
| SCHEMBL22747342 | 0.80 | KDM5B (0.47) | KDM4CKDM5BKDM5A | |
| SCHEMBL24180187 | 0.74 | CYP11B1 (0.46) | KDM4CKDM5BKDM5A | |
| SCHEMBL22747343 | 0.73 | CPB2 (0.49) | PHF8KDM4CKDM5BKDM5A | |
| SCHEMBL19220556 | 0.72 | KDM5B (0.43) | KDM4CKDM5BKDM5A | |
| SCHEMBL22185256 | 0.72 | CYP11B1 (0.45) | PHF8KDM4CKDM5B | |
| SCHEMBL24844792 | 0.69 | PHF8 (0.51) | PHF8KDM4CKDM2BKDM2AKDM5B | |
| SCHEMBL11914065 | 0.68 | CPB2 (0.32) | — | |
| SCHEMBL6529662 | 0.66 | PHF8 (0.54) | PHF8KDM4CKDM2BKDM2AKDM5B | |
| SCHEMBL8244665 | 0.66 | GABRA1 (0.50) | AKR1B1CXCR2P2RX7CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202404-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | PHF8 1854/4885KDM4C 712/4885KDM2B 980/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | PHF8 1854/4885KDM4C 712/4885KDM2B 980/4885 |
| US-10202404-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | PHF8 1854/4885KDM4C 712/4885KDM2B 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.